Mesoblast to meet with U.S. FDA over potential non-opioid treatment for chronic back pain

Mesoblast (ASX:MSB) will meet with the U.S. Food and Drug Administration (FDA) next month to discuss new data showing significant reductions in opioid use among patients treated with its investigational cell therapy rexlemestrocel-L for chronic low back pain. …